Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115088
Chunk: 34

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 34
---
 “Scilex Holding Company”. Our principal executive offices are located at 960 San Antonio Road, Palo Alto, California 94303, and our telephone number is (650) 516-4310.Our website address is www.scilexholding.com. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way part of this prospectus and should not be relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. You may obtain any of the documents filed by us with the SEC at no cost from the SEC’s website at http://www.sec.gov.

20

THE OFFERING Resale of Common Stock

| Shares of Common Stock offered by the Selling Stockholder | Up to 6,685,714 shares of our Common Stock, consisting of (i) 6,500,000 Penny Warrant Shares and (ii) 185,714 Issued Shares. |

| Shares of Common Stock outstanding before this Offering(1) | 6,951,671 shares of Common Stock (as of March 31, 2025). |

| Shares of Common Stock outstanding after the Offering and giving effect to the issuance of 6,500,000 shares of Common Stock | 13,451,671 shares of Common Stock (based on total shares outstanding as of March 31, 2025). |

| Terms of the Offering | The Selling Stockholder will determine when and how it will dispose of any shares of Common Stock registered under this prospectus for resale. |

| Use of proceeds | We will not receive any proceeds from the sale of shares of Common Stock by the Selling Stockholder. However, to the extent the Penny Warrants are exercised for cash, if at all, we will receive the exercise price of the Penny Warrants in an amount of up to an aggregate of $65,000, assuming the exercise in full of the remaining Penny Warrants. Each Penny Warrant entitles the holder thereof to purchase one share of Common Stock at a price of $0.01 per share. We currently intend to use the proceeds (if any) from the exercise of the Penny Warrants for cash for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment